FTRENasdaqServices-Medical LaboratoriesFiscal year ends December 31

Fortrea Holdings Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$22.42−0.07 (-0.31%)

Close on Oct 19, 2026

Market cap: $2.13B
P/E (TTM): –
Dividend yield: –

Fortrea Holdings Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	2,723	2,696	2,843	2,837	3,058
Cost of Revenue	2,220	2,162	2,252	2,113	2,453
Gross Profit	504	534	591	724	604
Selling, General & Admin	456	561	448	416	303
Total Costs & Expenses	3,596	2,858	2,811	2,650	2,943
Operating Income	-873	-162	32	187	114
Interest Expense	–	–	0.10	0.20	0.20
Other Non-Operating Income	7.90	21	6.90	2.10	2.10
Merger & Restructuring Charges	34	42	21	26	17
Asset Impairment Charges	798	0	0	9.80	0
Gain (Loss) on Sale of Assets	0	-20	0	0	–
Pretax Income	-983	-275	-31	187	136
Income Tax Expense	3.20	-3.50	1.20	41	38
Income from Continuing Operations	-986	-272	-32	146	–
Income from Discontinued Operations	0	-57	6.50	40	–
Net Income	-986	-329	-25	186	98
Net Income to Common	–	–	-3.40	193	98
EPS (Basic)(per share)	-10.81	-3.67	-0.29	2.09	1.10
EPS (Diluted)(per share)	-10.81	-3.67	-0.29	2.09	1.10
Shares Outstanding (Basic, Weighted)(shares)	–	90	89	89	89
Shares Outstanding (Diluted, Weighted)(shares)	–	90	89	89	89
EBITDA	-795	-75	130	281	281
Net Interest Income	–	–	-70	-0.20	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 19.3%
Operating margin: -0.4%
Net margin: -3.2%
Return on equity, FY2025: -102.4%

Financial strength

Current ratio: 0.96
Debt to equity: 2.01
Debt to assets: 38.8%
Cash to current liabilities: 17.5%

Valuation

P/E ratio: –
Price to sales: 0.79
Price to book: 4.05
Dividend yield: –